Yes Beno very likely in the next few weeks a pharma company will offer you 3 x market cap for a share of revenue in a pre phase 2 asset that has absolutely no human efficacy data whatsoever. Sounds very very plausible.
Ann: Investor webinar presentation, page-6
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.89M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 2.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 34000 | 1 |
View Market Depth
| Last trade - 09.00am 19/06/2024 (20 minute delay) ? |
| 1AD (ASX) Chart |
Day chart unavailable